CHAMPIONS ONCOLOGY INC
CSBRNASDAQTrading Snapshot
- Day Range
- $4.95 – $5.02
- 52-Week Range
- $4.88 – $8.74
- Volume
- $4.41B
- Avg Volume
- $4.98B
- Shares Outstanding
- 13.9M
- Next Earnings
- Sep 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $59M
- Last Q Revenue
- $14M
- P/E Ratio
- -62.4
- P/S Ratio
- 1.2x
- EPS (TTM)
- $-0.08
- Dividend Yield
- 0.00%
Why Investors Own CSBR
- ✓High-growth profile — revenue up +25.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 78% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About CHAMPIONS ONCOLOGY INC
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push
Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.
Champions Oncology Inc (CSBR) (Q4 2026) Earnings Call Highlights: Record Revenue and Positive ...
Champions Oncology Inc (CSBR) achieved record annual revenue of $59.4 million and its fourth consecutive quarter of positive adjusted EBITDA, despite a significant drop in data-license revenue.
Champions Oncology Q4 Earnings Call Highlights
Champions Oncology (NASDAQ:CSBR) reported record revenue for fiscal 2026 and positive adjusted EBITDA in every quarter of the year, supported by growth in its core Translational Oncology Solutions, or TOS, services business and efforts to bring radiopharmaceutical work in-house. For the fourth quar
Champions Oncology (NASDAQ:CSBR) Surges on Earnings Beat and Margin Expansion, Highlighting Quality Growth Stock
Champions Oncology beat Q4 revenue estimates, posted record FY2026 sales of $59.4M, and saw margins improve; stock surged 9.7% after-hours.
Champions Oncology Reports Record Annual Revenue of $59 Million
Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA HACKENSACK, NJ / ACCESS Newswire / July 27, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, ...